drugset / Trial / NCT03767452
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
Phase 4
Unknown
20 enrolled
Manhattan Medical Research Practice, PLLC
Endo USA Inc., a Keenova Therapeutics Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.
Timeline
- Start
- 2018-10-04
- Primary completion
- 2019-12
- Completion
- 2020-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.58 mg | Other |